Cape Town, South Africa  
March 1\textsuperscript{st}–2\textsuperscript{nd}, 2019

Update on Melanoma/Skin Cancer 2019  
3\textsuperscript{rd} International Educational Symposium of the MWS

Course Directors
Claus Garbe, Tuebingen, Germany  
Axel Hauschild, Kiel, Germany  
Dagmar Whitaker, Cape Town, South Africa
The following missions will guide the activities of MWS:

**Improve Medical Education**
MWS will host the World Congress of Melanoma every four years, following the tradition since 1985. MWS will care for grants in order to make attendance of physicians from developing countries possible. MWS will organize the World Meeting of Melanoma/Skin Cancer Centers annually in between the World Congress of Melanoma. MWS will support educational meetings in countries with less experience in melanoma diagnosis and treatment.

**Improve Guideline Development**
MWS intends to unify diagnostic and therapeutic strategies in melanoma worldwide. MWS will establish a MELANOMA KNOWLEDGE DATABASE (MKD), which contains all relevant articles for evidence based medicine in melanoma, and additionally evidence tables of these articles. MKD will be accessible for all national guideline groups. MWS will organize international expert meetings in order to develop recommendations for diagnosis and treatment of melanoma in the rapidly changing landscape.

**Improve Patient’s Access to New Treatments**
MWS intends to provide melanoma patients worldwide access to new and more efficacious treatments. MWS will address governments in order to achieve a more rapid reimbursement of new treatments. MWS will address pharmaceutical companies in order to achieve access to new treatment modalities in countries, where the high costs cannot be reimbursed.

**Improve Clinical Research in Melanoma**
MWS will coordinate clinical research activities in melanoma internationally. MWS will perform international clinical trials in indications, which are not investigated by the pharmaceutical industries. MWS will support international expert meetings in order to coordinate clinical research.
## Friday, March 1st, 2019

### 08:00–09:00 Global incidence and mortality rates of skin cancer

**Chairs:** Jean Jacques Grob, Dagmar Whitaker

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–08:12</td>
<td>Non-melanoma skin cancer</td>
</tr>
<tr>
<td></td>
<td>Claus Garbe, Tuebingen, Germany</td>
</tr>
<tr>
<td>08:15–08:27</td>
<td>Melanoma</td>
</tr>
<tr>
<td></td>
<td>Jean Jacques Grob, Marseille, France</td>
</tr>
<tr>
<td>08:30–08:37</td>
<td>Update on epidemiology in South Africa</td>
</tr>
<tr>
<td></td>
<td>Caradee Wright, Johannesburg, South Africa</td>
</tr>
<tr>
<td>08:40–09:00</td>
<td>Panel discussion: Falling rates in the foreseeable future?</td>
</tr>
<tr>
<td></td>
<td>Claus Garbe, Jean Jacques Grob, Dagmar Whitaker</td>
</tr>
</tbody>
</table>

### 09:00–10:00 Dermoscopic diagnosis of skin cancer

**Chairs:** Gary Levy, Iris Zalaudek

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–09:27</td>
<td>Pigmented lesions</td>
</tr>
<tr>
<td></td>
<td>Gary Levy, Johannesburg, South Africa</td>
</tr>
<tr>
<td>09:30–09:57</td>
<td>Pink lesions</td>
</tr>
<tr>
<td></td>
<td>Iris Zalaudek, Trieste, Italy</td>
</tr>
</tbody>
</table>

10:00–10:30 Coffee Break

### 10:30–11:00 Key note lecture

**Chair:** Alberto Wainstein

New devices for skin cancer diagnosis

**Axel Hauschild, Kiel, Germany**

### 11:00–12:00 Controversy: Lymph node surgery improves survival

**Chairs:** Roland Kaufmann, Alberto Wainstein

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00–11:17</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Alex Landau, Cape Town, South Africa</td>
</tr>
<tr>
<td>11:20–11:37</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Claus Garbe, Tuebingen, Germany</td>
</tr>
<tr>
<td>11:40–12:00</td>
<td>Panel discussion: The future of CLND</td>
</tr>
<tr>
<td></td>
<td>Alberto Wainstein, Roland Kaufmann, Alex Landau</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:00–13:00</td>
<td>Satellite Symposium Roche with lunch bags</td>
</tr>
<tr>
<td>13:00–13:30</td>
<td>Break</td>
</tr>
<tr>
<td>13:30–14:30</td>
<td><strong>Controversy: Adjuvant treatment for BRAF mutated melanoma</strong>&lt;br&gt;<strong>Chair:</strong> Axel Hauschild, Jean Jacques Grob</td>
</tr>
<tr>
<td>13:30–13:42</td>
<td>PD-Antibodies first&lt;br&gt;<strong>Jean Jacques Grob,</strong> Marseille, France</td>
</tr>
<tr>
<td>13:45–13:57</td>
<td>Dabrafenib plus Trametinib first&lt;br&gt;<strong>Grant McArthur,</strong> Melbourne, Australia</td>
</tr>
<tr>
<td>14:00–14:12</td>
<td>Is there still a role for interferon treatment?&lt;br&gt;<strong>Sameera Dalvie,</strong> Cape Town, South Africa</td>
</tr>
<tr>
<td>14:15–14:30</td>
<td>Panel discussion: Which treatment first?&lt;br&gt;<strong>Axel Hauschild,</strong> <strong>Grant McArthur,</strong> Jean Jacques Grob</td>
</tr>
<tr>
<td>14:30–15:30</td>
<td><strong>Oncogene-driven treatment of advanced melanoma</strong>&lt;br&gt;<strong>Chairs:</strong> Dirk Schadendorf, Willie Visser</td>
</tr>
<tr>
<td>14:30–14:42</td>
<td>Molecular testing in melanoma:&lt;br&gt;update 2019&lt;br&gt;<strong>Christopher Philipp Maske,</strong> Johannesburg, South Africa</td>
</tr>
<tr>
<td>14:45–14:57</td>
<td>Update on targeted therapies&lt;br&gt;<strong>Dirk Schadendorf,</strong> Essen, Germany</td>
</tr>
<tr>
<td>15:00–15:12</td>
<td>Management of adverse events&lt;br&gt;<strong>Willie Visser,</strong> Cape Town, South Africa</td>
</tr>
<tr>
<td>15:15–15:30</td>
<td>Panel discussion: Perspectives of targeted therapy&lt;br&gt;<strong>Christopher Philipp Maske,</strong> Willie Visser, Dirk Schadendorf</td>
</tr>
<tr>
<td>15:30–16:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>16:00–17:00</td>
<td><strong>Immunotherapy of advanced melanoma</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Jean Jacques Grob, Willie Visser</td>
</tr>
<tr>
<td>16:00–16:17</td>
<td>Mechanisms of immune checkpoint modulation</td>
</tr>
<tr>
<td></td>
<td>Christoffer Gebhardt, Hamburg, Germany</td>
</tr>
<tr>
<td>16:20–16:37</td>
<td>Update on clinical trials</td>
</tr>
<tr>
<td></td>
<td>Jean Jacques Grob, Marseille, France</td>
</tr>
<tr>
<td>16:40–16:57</td>
<td>Management of autoimmune events</td>
</tr>
<tr>
<td></td>
<td>Willie Visser, Cape Town, South Africa</td>
</tr>
<tr>
<td>17:00–17:30</td>
<td><strong>Key note lecture</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Dirk Schadendorf</td>
</tr>
<tr>
<td></td>
<td>Combinational approaches in metastatic melanoma: the future!?</td>
</tr>
<tr>
<td></td>
<td>Grant McArthur, Melbourne, Australia</td>
</tr>
<tr>
<td>17:30–18:30</td>
<td><strong>Systemic treatment of advanced non-melanoma skin cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Willie Visser, Christoffer Gebhardt</td>
</tr>
<tr>
<td>17:30–17:47</td>
<td>Basal cell carcinoma</td>
</tr>
<tr>
<td></td>
<td>Bianca Tod, Cape Town, South Africa</td>
</tr>
<tr>
<td>17:50–18:07</td>
<td>Merkel cell carcinoma</td>
</tr>
<tr>
<td></td>
<td>Christoffer Gebhardt, Hamburg, Germany</td>
</tr>
<tr>
<td>18:10–18:27</td>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td></td>
<td>Axel Hauschild, Kiel, Germany</td>
</tr>
<tr>
<td>18:30</td>
<td>Get-together in the industrial exhibition</td>
</tr>
</tbody>
</table>
Saturday, March 2nd, 2019

08:00–09:00 Sunscreens protect against skin cancer!
Chairs: Jean Jacques Grob, Dagmar Whitaker

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–08:17</td>
<td>Jean Jacques Grob</td>
<td>Marseille, France</td>
</tr>
<tr>
<td>08:20–08:37</td>
<td>Claus Garbe</td>
<td>Tuebingen, Germany</td>
</tr>
<tr>
<td>08:40–09:00</td>
<td>Panel discussion: Primary prevention of skin cancer</td>
<td>Claus Garbe, Jean Jacques Grob, Dagmar Whitaker</td>
</tr>
</tbody>
</table>

09:00–10:00 Interdisciplinary case discussions: Melanoma
Chair: Dirk Schadendorf

Case discussion panel
Roland Kaufmann, Dirk Schadendorf

<table>
<thead>
<tr>
<th>Time</th>
<th>Case</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–09:12</td>
<td>Case one</td>
<td>Charles Thatcher</td>
<td>Johannesburg, South Africa</td>
</tr>
<tr>
<td>09:15–09:27</td>
<td>Case two</td>
<td>Sameera Dalvie</td>
<td>Cape Town, South Africa</td>
</tr>
<tr>
<td>09:30–09:42</td>
<td>Case three</td>
<td>Johann De Wet</td>
<td>Cape Town, South Africa</td>
</tr>
<tr>
<td>09:45–09:50</td>
<td>Case four</td>
<td>Rupesh Misra</td>
<td>East London, South Africa</td>
</tr>
</tbody>
</table>

10:00–10:30 Coffee Break with guided Poster Viewing
10:30–11:30 Interdisciplinary case discussion session: Non melanoma skin cancer
Chair: Willie Visser

Case discussion panel
Willie Visser, Christoffer Gebhardt, Iris Zalaudek

11:15–11:27 Case one
Willie Visser, Cape Town, South Africa

11:30–11:42 Case two
Christoffer Gebhardt, Hamburg, Germany

11:45–11:57 Case three
Iris Zalaudek, Trieste, Italy

12:00–12:12 Case four
Johann De Wet, Cape Town, South Africa

11:30–12:30 Follow-up examinations: How often, how long, which procedures?
Chairs: Claus Garbe, Dagmar Whitaker

12:15–12:27 Follow-up of melanoma
Claus Garbe, Tuebingen, Germany

12:30–12:42 Follow-up of non-melanoma skin cancer
Dagmar Whitaker, Cape Town, South Africa

12:45–13:15 Panel discussion
Claus Garbe, Dirk Schadendorf, Dagmar Whitaker

12:30–13:00 Lunch Break

13:00–16:00 Dermoscopy Course
Case-based discussions on melanoma and non-melanoma skin cancer
Iris Zalaudek, Robert Weiss

16:00 End of conference
Congress Faculty

D

Sameera Dalvie, MD
College of Radiation Oncology
Groote Schuur Hospital
Main Rd, Observatory
Cape Town
South Africa

Johann De Wet, MD
Division of Dermatology, Department of Medicine
Stellenbosch University
Tygerberg Hospital
Cape Town
South Africa

G

Claus Garbe, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen
Germany

Christoffer Gebhardt, MD
Skin Cancer Center
University Hospital Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg
Germany

Jean Jacques Grob, MD
Professor of Dermatology
Service de Dermatology and Cancer Research
Hospital de la Timone
264 Rue St. Pierre
13005 Marseille
France

H

Axel Hauschild, MD
Professor of Dermatology
Department of Dermatology
University of Kiel
Rosalind-Franklin-Str. 7
24105 Kiel
Germany

K

Roland Kaufmann, MD
Professor of Dermatology, Director
Department of Dermatology
Clinical Center J. W. Goethe University
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Germany

L

Alex Gil Landau, MD
Room 201 Fairfield Medical Suites
Wildernes Road
Claremont, Cape Town 7708
South Africa

Gary Levy, MD
Suite 1A Rochester Place
173 Rivonia Road
Johannesburg
South Africa

M

Christopher Philipp Maske, MD
Lancet Corner Building
Cnr Stanley Avenue & Napier Road
Richmond, 2092
Johannesburg
South Africa
Grant McArthur, MD
Professor of Medicine
Head Cancer Therapeutics Program
Head Skin and Melanoma Service
Divisions of Cancer Medicine and Research
Peter MacCallum Cancer Centre
Locked Bag 1A’Beckett St
Melbourne 8006
Australia

Rupesh Misra, MD
University of Cape Town
East London
South Africa

Dirk Schadendorf, MD
Professor of Dermatology
Department of Dermatology
University Hospital Essen
Hufelandstr. 55
45147 Essen
Germany

Charles Thatcher, MD
Eighth Avenue, Parktown North
Johannesburg, Gauteng
South Africa

Bianca Tod, MD
Stellenbosch University
Tygerberg Academic Hospital
Cape Town
South Africa

V

Willie Visser, MD
Head of Dermatology
Division of Dermatology
Departement Geneeskunde Faculty of Medicine and Health Sciences
Stellenbosch University
Posbus 241, Cape Town
South Africa

W

Alberto Wainstein, MD
Professor of Medicine
Medical Science Faculty of Minas Gerais (CMMG)
Belo Horizonte
Brazil

Robert Weiss, MD
Private Practice in Johannesburg
37A Keyes Avenue, Rosebank,
Johannesburg 2196
South Africa

Dagmar Whitaker, MD
1 Wytham Ave, Kenilworth Cape Town
Western Cape
South Africa

Caradee Wright, MD
Associate Professor
University of Johannesburg
Johannesburg
South Africa

Z

Iris Zalaudek, MD
Head of the Dermatology Clinic
University of Trieste
Hospital Maggiore
Piazza dell’ Ospedale 1
34125 Trieste
Italy
General Information

Exhibition Opening Hours
Friday, March 1st: 07:30–19:00
Saturday, March 2nd: 07:30–16:30

Insurance
The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance.

Language
The official language of the meeting is English. Simultaneous translation will not be provided.

Meeting Organization

**MEDCONCEPT**

MedConcept
Gesellschaft für medizinische Projekte mbH
Mr Christopher Huhn
Friedenstraße 58
15366 Neuenhagen b. Berlin, Germany
Phone: +49 (0)3342 42689-30
Fax: +49 (0)3342 42689-40
Email: christopher.huhn@medconcept.org or info@medconcept.org
www.medconcept.org

Meeting Venue

The Rotunda
69 Victoria St
Camps Bay, Cape Town, 8001
South Africa
Phone: +27 (0)21 430 4444
Email: res@thebay.co.za

The registration desk is situated at the entrance of the Rotunda.
Registration Desk Opening Hours
Thursday, February 28th: 16:00–18:00 (early check-in)
Friday, March 1st: 07:00–19:00
Saturday, March 2nd: 07:00–17:00

Registration Fees

<table>
<thead>
<tr>
<th></th>
<th>Early registration until Jan. 31st</th>
<th>From Feb. 1st until Feb. 22nd</th>
<th>Late Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full Delegates</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Africa</td>
<td>3,000 Rand</td>
<td>3,500 Rand</td>
<td>4,000 Rand</td>
</tr>
<tr>
<td>Rest of World</td>
<td>300 Euro</td>
<td>350 Euro</td>
<td>400 Euro</td>
</tr>
</tbody>
</table>

Cancellation Policy
Cancellations must be received in writing by January 25th, 2019. No refunds will be granted after that date. To cancel a registration, please send an Email to info@medconcept.org. A processing fee of 150 Rand for Africa and 30 Euro for the Rest of the World will be deducted from each cancelled registration.

Substitutions are possible and must be received in writing by February 15th, 2019. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.
## Sponsors

### Gold

<table>
<thead>
<tr>
<th>Roche</th>
<th>Roche</th>
</tr>
</thead>
</table>

### Silver

<table>
<thead>
<tr>
<th>Bristol-Myers Squibb</th>
<th>Bristol-Myers Squibb</th>
</tr>
</thead>
</table>

### Bronze

<table>
<thead>
<tr>
<th>MSD</th>
<th>MSD</th>
</tr>
</thead>
</table>

### Further Sponsors

<table>
<thead>
<tr>
<th>Beiersdorf</th>
<th>Beiersdorf</th>
</tr>
</thead>
<tbody>
<tr>
<td>BioDerma</td>
<td>BioDerma</td>
</tr>
<tr>
<td>BioNike</td>
<td>BioNike</td>
</tr>
<tr>
<td>Fotofinder</td>
<td>Fotofinder</td>
</tr>
<tr>
<td>Galderma</td>
<td>Galderma</td>
</tr>
<tr>
<td>Genop Healthcare</td>
<td>Genop Healthcare</td>
</tr>
<tr>
<td>ISDIN</td>
<td>ISDIN</td>
</tr>
<tr>
<td>Novartis</td>
<td>Novartis</td>
</tr>
</tbody>
</table>
Zelboraf® in patients with BRAF V600E mutation - positive metastatic melanoma: ¹,²

- Produces a robust increase in progression-free survival compared to dacarbazine: 6.9 months vs 1.6 months (HR 0.39; p < 0.0001) ¹

- Zelboraf® is associated with a highly significant improvement in response rate vs dacarbazine (59% vs 11%) ¹

- Medium time to response with Zelboraf® is 1.4 months ¹

- A well-characterised, manageable safety profile ²
